Pfizer Pulls Menopause Hormone Therapy Premarin From Canadian Market
Summary
Pharmaceutical company Pfizer is discontinuing the sale of its menopause hormone replacement therapy Premarin in the Canadian market. This decision follows an internal company review and will affect both the vaginal cream and oral tablet versions of the medication.
Pfizer Inc. (NYSE:PFE) will reportedly no longer sell its hormone replacement therapy Premarin in Canada following an internal review, ending Canadian availability of both its vaginal cream and three oral tablet strengths. Pfizer Canada confirmed to Reuters on Thursday that it will supply no further batches of Premarin vaginal cream, which treats menopause symptoms and has experienced shortages in Canada…
Source: Read the full story at Top Stories Feed
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.